Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Mar 15, 2022Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Aug 12, 2021Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Jun 27, 2021Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS
Jun 13, 2021Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Oct 14, 2020Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Trial
Aug 18, 2020Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation